Back to Ovarian Cancer
NCT03480750
NCT03480750
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by a tissue sample after surgery
- Your cancer came back for the first time within 1 year of finishing your initial platinum-based chemotherapy, or your cancer continued to grow during that chemotherapy
- You are generally able to care for yourself and carry out daily activities (your doctor would assess this using a standard scale)
- Your bone marrow is working well enough, meaning your blood counts (white blood cells, red blood cells, and platelets) are at acceptable levels
- Your kidneys and liver are functioning at an acceptable level, based on blood test results
- If you are able to become pregnant, you must agree to use effective birth control for the entire time you are in the study
- There is no other available treatment expected to extend your life by at least 3 months
Who may not be able to join:
- Your cancer has spread to the brain or spinal cord
- You have had another type of cancer in the past 5 years (except for certain very early-stage cervical changes or common skin cancers)
- You are currently receiving chemotherapy
- You have not fully recovered from surgery within the last 4 weeks
- You have a serious medical condition that could be made worse by treatment or that cannot be kept under control
- You have medical or mental health issues severe enough to prevent you from safely following the study requirements
- You have had a severe allergic reaction to the study drugs or similar medications
- You are pregnant or currently breastfeeding
- You have trouble swallowing, a bowel blockage, or a condition that prevents your body from absorbing nutrients properly
- You are unwilling or unable to give your informed consent to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
National Cheng-Kung University Hospital
Registry
clinicaltrials_gov
Start date
1 September 2012
Est. completion
1 October 2015
Primary endpoints
Number of Participants With Dose-Limiting Toxicity (DLT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.